Table 1.
Demographic and clinical profile of the patients (N = 244)
| Gender (male), n (%) | 206 (84.4) |
| Median age (range), years | 67 (28–88) |
| Mean body mass index (range), kg/m2 | 23.5 (15.6–40.4) |
| ASA score ≥3, n (%) | 134 (54.9) |
| ECOG performance status ≥2, n (%) | 13 (5.3) |
| Diabetes mellitus, n (%) | 113 (46.7) |
| Hypertension, n (%) | 160 (65.6) |
| Hepatitis B carrier (positive for HBsAg), n (%) | 116 (47.5) |
| Alcohol consumption, n (%) | 48 (19.7) |
| Median albumin (range), g/L | 38.0 (22–48) |
| Median bilirubin (range), µmol/L | 15.5 (4–100) |
| Median creatinine (range), µmol/L | 82 (34–828) |
| Median prothrombin time (range), s | 13.3 (11.9–34.5) |
| Median platelet count (range), ×109/L | 202 (43.3–1,445) |
| Child-Pugh class, n (%) | |
| A | 223 (91.4) |
| B | 20 (8.2) |
| C | 1 (0.4) |
| ICG dye retention test | |
| Performed, n (%) | 203 (83.2) |
| Mean (range) (n = 203), % | 9.32 (1.8–35.0) |
| Liver parenchyma, n (%) | |
| Fatty | 43 (17.6) |
| Cirrhotic | 154 (63.1) |
| Normal | 47 (19.3) |
| Previous treatment, n (%) | |
| Transarterial chemoembolization | 15 (6.1) |
| Portal vein embolization | 4 (1.6) |
| Radiofrequency ablation | 8 (3.3) |
ASA, American Society of Anesthesiologists score; ECOG, Eastern Cooperative Oncology Group; ICG, indocyanine green.